Valo Therapeutics Secures €19M in Funding to Advance PeptiCRAd Cancer Immunotherapy, Mar. 10, 2025
Valo Therapeutics has secured €19M in funding to advance its PeptiCRAd cancer immunotherapy platform. The investment will support Phase 1B clinical trials in Italy, Australia, and Germany. A new R&D center in Naples will focus on patient enrollment, virus manufacturing, and local research initiatives.
Full Article: Valo Therapeutics Secures €19M in Funding to Advance PeptiCRAd Cancer Immunotherapy
Agomab Reports Positive Interim Results for AGMB-129 in Crohn’s Disease Trial, Mar. 10, 2025
Agomab Therapeutics has reported positive interim Phase IIa results for AGMB-129, an oral ALK5 inhibitor for fibrostenosing Crohn’s disease. The trial met safety, tolerability, and target engagement endpoints in 44 patients. The company has launched an open-label extension for up to 48 weeks, signaling strong confidence in the drug’s potential.
Full Article: Agomab Reports Positive Interim Results for AGMB-129 in Crohn’s Disease Trial
MSInsight Raises €1.6M Seed Funding for MSI Cancer Diagnostic Software, Mar. 10, 2025
MSInsight has secured €1.6M in seed funding to advance its MSIcare, AI-driven diagnostic software for detecting Microsatellite Instability (MSI) cancers. The funding will support further development and regulatory validation, particularly for Lynch syndrome and pediatric oncology applications, aiming to improve diagnostic accuracy and guide immunotherapy decisions.
Full Article: MSInsight Raises €1.6M Seed Funding for MSI Cancer Diagnostic Software
Johnson & Johnson Ends Partnership with Genmab on Darzalex Successor After Phase 1/2 Data, Mar. 10, 2025
Johnson & Johnson has opted out of licensing Genmab's CD38 monoclonal antibody, HexaBody-CD38, after reviewing Phase 1/2 data. This decision has led to the discontinuation of the development program, which was initially aimed at creating a successor to their multiple myeloma treatment, Darzalex.
Full Article: Johnson & Johnson Ends Partnership with Genmab on Darzalex Successor After Phase 1/2 Data
Lentitek Secures £700,000 in Private Funding to Advance Cancer Therapies, Mar. 11, 2025
Lentitek Ltd, an Edinburgh-based biotech, has secured £700,000 in private funding, bringing its total investment to £1 million over six months, including a £300,000 Innovate UK grant. The funding will support the development of its viral vector technology, which is critical for the next generation of cancer treatments, including CAR-T and gene therapies. Lentitek aims to overcome scalability and cost barriers to make these therapies more accessible to patients.
Full Article: Lentitek Secures £700,000 in Private Funding to Advance Cancer Therapies
MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee for MaaT013 in aGvHD, Mar. 11, 2025
MaaT Pharma has received a positive opinion from the European Medicines Agency's Pediatric Committee for the Pediatric Investigation Plan (PIP) of MaaT013 in acute Graft-versus-Host Disease (aGvHD). This regulatory milestone supports the start of a pediatric trial in 2026 and could lead to market exclusivity for MaaT013 in Europe by late 2026, providing new options for patients in need of innovative therapies for aGvHD.
Full Article: MaaT Pharma Receives Positive Opinion from EMA Pediatric Committee for MaaT013 in aGvHD
Hansa Biopharma Completes Enrollment in European Phase 3 Study for Imlifidase in Kidney Transplant Patients, Mar. 11, 2025
Hansa Biopharma has completed enrollment for its Phase 3 PAES study evaluating the one-year survival of highly sensitized kidney transplant patients treated with imlifidase (IDEFIRIX). The study, which includes 50 treated patients and a reference cohort, aims to secure full EMA approval for IDEFIRIX. The data is expected in H2 2026 and could expand access to this therapy for patients facing long transplant wait times.
Full Article: Hansa Biopharma Completes Enrollment in European Phase 3 Study for Imlifidase in Kidney Transplant Patients
OKYO Pharma Files for US FDA Fast Track Designation for Urcosimod in Neuropathic Corneal Pain, Mar. 11, 2025
OKYO Pharma has filed for Fast Track designation with the FDA for urcosimod (formerly OK-101) to treat neuropathic corneal pain (NCP), a severe eye condition with no approved treatments. The designation would allow for expedited FDA review and closer collaboration on regulatory requirements. Urcosimod has shown statistical significance in a Phase 2 dry eye disease trial and is now progressing in a Phase 2 trial for NCP.
Full Article: OKYO Pharma Files for US FDA Fast Track Designation for Urcosimod in Neuropathic Corneal Pain
Coherus BioSciences Announces Workforce Reduction Due to Udenyca Sale to Accord, Mar. 11, 2025
Coherus BioSciences will reduce its workforce by 30% following the sale of its Neulasta biosimilar, Udenyca, to Accord BioPharma. Approximately 50 employees associated with Udenyca will transition to Accord as part of the agreement, which will impact Coherus' operational structure. This move follows Coherus' financial realignment after the Udenyca deal.
Full Article: Coherus BioSciences Announces Workforce Reduction Due to Udenyca Sale to Accord
Pfizer and Arvinas Report Mixed Survival Results in Phase 3 Study for Vepdegestrant in ER+/HER2- Breast Cancer, Mar. 11, 2025
Pfizer and Arvinas’ estrogen receptor degrader, vepdegestrant, has shown mixed survival results in its first Phase 3 test for ER+/HER2- advanced breast cancer. While the therapy failed a key endpoint, both companies noted success in a subpopulation, suggesting that vepdegestrant may still have a viable regulatory path. The drug is a PROTAC ER degrader being tested against AstraZeneca’s Faslodex in patients who had already received CDK 4/6 inhibitors.
Full Article: Pfizer and Arvinas Report Mixed Survival Results in Phase 3 Study for Vepdegestrant in ER+/HER2- Breast Cancer
Bristol Myers Squibb to Acquire 2seventy Bio for $286 Million, Mar. 11, 2025
Bristol Myers Squibb has announced plans to acquire 2seventy Bio for $286 million, gaining full rights to Abecma® (idecabtagene vicleucel), a BCMA-directed CAR T-cell therapy for multiple myeloma. This acquisition follows 2seventy's financial struggles despite the expanded FDA approval of Abecma in 2023 for earlier treatment lines in multiple myeloma. The companies have been collaborating on clinical trials to further explore Abecma's potential.
Full Article: Bristol Myers Squibb to Acquire 2seventy Bio for $286 Million
atai Life Sciences Doses First Patient in Phase 2 Elumina Trial for VLS-01 in Treatment-Resistant Depression, Mar. 12, 2025
atai Life Sciences has announced the first patient dosed in the Phase 2 Elumina trial evaluating VLS-01, an oral transmucosal film formulation of DMT, for treatment-resistant depression (TRD). The trial (NCT06524830) will assess the efficacy, safety, and durability of two doses of VLS-01 vs. placebo, with topline results expected in Q1 2026. A second treatment period will explore different dose levels to further evaluate long-term effects.
Full Article: atai Life Sciences Doses First Patient in Phase 2 Elumina Trial
Roche and Zealand Pharma Collaborate on Petrelintide for Weight Management, Mar. 12, 2025
Roche has entered into an exclusive collaboration and licensing agreement with Zealand Pharma to co-develop and co-commercialize petrelintide, an amylin analog currently in Phase 2 development for weight management. The partnership will also explore a fixed-dose combination of petrelintide with Roche’s dual GLP-1/GIP receptor agonist CT-388, aiming to enhance efficacy and tolerability in obesity treatment. Zealand Pharma will receive up to $5.3 billion, including $1.65 billion upfront and milestone-based payments.
Full Article: Roche and Zealand Pharma Collaborate on Petrelintide for Weight Management
Mainz Biomed and Liquid Biosciences Partner on mRNA Biomarkers for Pancreatic Cancer Detection, Mar. 13, 2025
Mainz Biomed has entered into a License and Option Agreement with Liquid Biosciences to develop a blood-based test for pancreatic cancer using novel mRNA biomarkers. The agreement grants Mainz an exclusive license with an option to acquire global rights, backed by Liquid’s proprietary EMERGE platform, which has demonstrated 95% sensitivity and 98% specificity in detecting pancreatic cancer. The companies aim for FDA approval to establish a new standard in early cancer detection.
Full Article: Mainz Biomed and Liquid Biosciences Partner on mRNA Biomarkers for Pancreatic Cancer Detection
Salipro Biotech and Boehringer Ingelheim Enter Research and Licensing Agreement, Mar. 13, 2025
Salipro Biotech has entered a research and license agreement with Boehringer Ingelheim to accelerate drug discovery for GPCRs, ion channels, and transporters in areas like mental health and cardio-renal-metabolic diseases. The collaboration will leverage Salipro’s Salipro® platform technology to stabilize challenging drug targets, enabling biophysical and structural studies such as cryo-electron microscopy. Salipro will receive research and milestone payments to support next-generation therapeutic development.
Full Article: Salipro Biotech and Boehringer Ingelheim Enter Research and Licensing Agreement
Heidelberg Pharma Amends Royalty Financing with Healthcare Royalty, Mar. 13, 2025
Heidelberg Pharma AG and HealthCare Royalty (HCRx) have amended their royalty financing agreement, securing an additional $20M upfront payment while eliminating a $15M sales-based milestone for 2025. The amendment provides non-dilutive financing, extending Heidelberg Pharma’s cash runway into 2027, as it anticipates an FDA approval decision by August for TLX250-CDx, a PET imaging agent for renal cancer.
Full Article: Heidelberg Pharma Amends Royalty Financing with Healthcare Royalty
HAYA Therapeutics Appoints Dr. Richard Law as Chief Business Officer, Mar. 13, 2025
HAYA Therapeutics has appointed Dr. Richard Law as Chief Business Officer (CBO) to drive strategic partnerships, fundraising, and business growth. With extensive experience in biopharma deals and company scaling, Dr. Law’s hiring signals HAYA’s focus on advancing collaborations, including its existing partnership with Eli Lilly, and securing new funding or licensing agreements.
Full Article: HAYA Therapeutics Appoints Dr. Richard Law as Chief Business Officer
Blue Earth Therapeutics Reports Positive Phase 1 Data for Lutetium (177Lu) rhPSMA-10.1 Injection, Mar. 13, 2025
Blue Earth Therapeutics has announced promising Phase 1 results for its Lutetium (177Lu) rhPSMA-10.1 Injection in metastatic castrate-resistant prostate cancer. The data shows higher absorbed radiation doses in tumors compared to critical healthy tissues, with ratios significantly exceeding first-generation PSMA-targeted radioligand therapies. This paves the way for Phase 2 trials to optimize treatment outcomes with innovative dosing regimens.
Full Article: Blue Earth Therapeutics Reports Positive Phase 1 Data for Lutetium (177Lu) rhPSMA-10.1 Injection
Basilea Pharmaceutica Receives Milestone Payment from Pfizer, Mar. 14, 2025
Basilea Pharmaceutica has received a USD 2.5 million milestone payment from Pfizer following strong sales of the antifungal Cresemba® (isavuconazole) in Asia Pacific and China. The milestone highlights Cresemba’s growing market presence in treating invasive mold infections. This is the first sales milestone in the region this year, with global sales of Cresemba reaching USD 533 million over the past 12 months.
Full Article: Basilea Pharmaceutica Receives Milestone Payment from Pfizer
MoonLake Immunotherapeutics Gears Up for Major Phase 3 Readout, Mar. 14, 2025
MoonLake Immunotherapeutics is preparing for a significant stock-moving event with the anticipated mid-year Phase 3 readout for its investigational therapy in a painful inflammatory skin condition. The results could greatly impact the company’s positioning in the biotech industry.
Full Article: MoonLake Immunotherapeutics Gears Up for Major Phase 3 Readout
